Posts

Pfizer advances Litfulo for vitiligo in face of Incyte and AbbVie competition

on

Chai Discovery raises $400M Series C for AI molecule models used by Lilly, Novartis and Pfizer

on

Pfizer'

on

Pfizer's first new ADC from Seagen acquisition fails Phase 3 NSCLC trial but may live on in earlier lines and combinations

on

Pfizer CFO to depart

on

Pfizer hunts for new CFO as Denton prepares to leave for consumer goods sector

on

ADA: Metsera asset data support Pfizer’s entry point into obesity market

on

Pfizer signs up to $10.5B deal with Innovent for 12 early‑stage cancer drugs from China's biotech hub

on

Pfizer's next-gen pneumonia shot beats Prevnar 20 in infant trial

on

BridgeBio's Attruby Challenges Pfizer's Tafamidis in ATTR-CM with Late-Stage Data Hinting at Superior Survival and Reduced Hospitalizations

on

Rigel Pharmaceuticals Secures Licensing Deal for Arvinas and Pfizer's FDA-Approved Breast Cancer Drug VEPPANU

on

Pfizer's 2029 Growth Story Bolstered by Q1 2026 Results and Vyndamax Patent Settlement

on

FDA Approves Arvinas and Pfizer's Veppanu (vepdegestrant), First PROTAC for ESR1-Mutated Breast Cancer

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

Pfizer Closes South San Francisco Office, Transitions Employees to Remote Roles

on

Pfizer and Valneva's Lyme Vaccine Misses Primary Endpoint But Pursue Regulatory Approval

on

Pfizer's Talzenna Approved for Earlier Use in Prostate Cancer Following Phase 3 Trial Success

on

Pfizer's Atirmociclib Delivers Positive Phase 2 Results in Metastatic Breast Cancer

on

China Approves Pfizer's GLP-1 Obesity Drug Xianweiying Shortly After Licensing Deal with Sciwind

on

Biopharma Bites: PhRMA Rebukes Trump's MFN Call, Pfizer Exercises Beam Base Editing Option, and Charles River Updates

on